Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.70 |
| ▸ | MTOR | P42345 | 3/20 | 0.69 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.69 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.69 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.69 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | STK16 | O75716 | 1/20 | 0.69 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.69 |
| ▸ | JAK1 | P23458 | 1/20 | 0.69 |
| ▸ | TYK2 | P29597 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191525 | 0.91 | PIK3CA (0.73) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL19391979 | 0.88 | PIK3CD (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL8231397 | 0.86 | PIK3CD (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL19143021 | 0.86 | PIK3CD (0.65) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL19142610 | 0.86 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL16908604 | 0.84 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL190172 | 0.84 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL13070764 | 0.84 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL14902876 | 0.83 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL19142522 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360386-A1 | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions | UNITY BIOTECHNOLOGY, INC. | 2020-11-19 | — | — | US | disclosed |
| EP-2766011-B1 | TREATMENT OF PHARMACOLOGICAL-INDUCED HYPOCHLORHYDRIA IN CANCER PATIENTS | GENENTECH INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PIK3CA 87/4885PIK3CD 215/4885PIK3CB 250/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PIK3CA 106/4885PIK3CD 153/4885PIK3CB 309/4885 |
| US-20200360386-A1 | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions | HSP90AB1, HSP90AB2P, HSP90AA1 | PIK3CA 156/4885PIK3CD 340/4885PIK3CB 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.